Have a personal or library account? Click to login
The role of Toll-like receptors (TLRs) in virus-related cancers: a mini review Cover

The role of Toll-like receptors (TLRs) in virus-related cancers: a mini review

Open Access
|Jan 2021

References

  1. 1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5): 373384.10.1038/ni.186320404851
  2. 2. Loganathan R, Nazeer M, Goda V, Devaraju P, Ali M, Karunakaran P, et al. Genetic variants of TLR4 and TLR9 are risk factors for chronic Helicobacter pylori infection in South Indian tamils. Hun Immunoy. 2017;78(2):216220.10.1016/j.humimm.2016.12.00227993530
  3. 3. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987995.10.1038/ni111215454922
  4. 4. So WY and Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci. 2010;6(7):675681.
  5. 5. Wang Q, Zhang X, Xiao T, Pan C, Liu X, Zhao Y. Prognostic role of Toll-like receptors in cancer: a meta-analysis. Ther Clin Risk Manag. 2018;14:1323330.10.2147/TCRM.S171341607164430104878
  6. 6. González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665.10.1186/1471-2407-10-665300968021129170
  7. 7. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15(3):266–82.10.1016/j.chom.2014.02.011399224324629334
  8. 8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.10.3322/caac.2010721296855
  9. 9. Zauner L, Nadal D. Understanding TLR9 action in Epstein-Barr virus infection. Front Biosci (Landmark Ed).2012;17:1219–31.10.2741/398222201799
  10. 10. Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. J Pathol. 2015;235(2):323333.10.1002/path.4448428067625251730
  11. 11. Liu S, Wang X, Shi Y, Han L, Zhao Z, Zhao Cd at al. Toll-like receptor gene polymorphisms and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma in Northern China. Saudi J Gastroenterol. 2015;21(2):95–103.10.4103/1319-3767.153832439258225843196
  12. 12. Tobouti PL, Bolt R, Radhakrishnan R, Machado de Sousa SCOd Hunter KD. Altered Toll-like receptor expression and function in HPV-associated oropharyngeal carcinoma. Oncotarget. 2018;9(1):236248.10.18632/oncotarget.18959578746129416610
  13. 13. Rickinson AB. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol. 2014;26:99–115.10.1016/j.semcancer.2014.04.00424751797
  14. 14. Ruuskanen M, Leivo I, Minn H, Vahlberg T, Haglund C, Hagström J, et al. Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma. BMC Cancer. 2019;19(1):624.10.1186/s12885-019-5816-9659360231238894
  15. 15. Aggarwal R, Misra S, Guleria C, Suri V, Mangat N, Sharma M, et al. Characterization of Toll-like receptor transcriptome in squamous cell carcinoma of cervix: a case-control study. Gynecol Oncol. 2015;138(2):358–62.10.1016/j.ygyno.2015.05.02926024767
  16. 16. Rich AM, Hussaini HM, Parachuru VPB, and Seymour GJ. Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Fronn Immunol. 2014;5:464.10.3389/fimmu.2014.00464417411625309546
  17. 17. Shi Y, Peng SL, Yang LF, Chen X, Tao YG, Cao Y. Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis. Chin J Cancer. 2016;35:16.10.1186/s40880-016-0079-1472412326801987
  18. 18. Sharma U, Singhal P, Bandil K, Patle R, Kumar A, Neyaz KD et al. Genetic variations of TLRs and their association with HPV/EBV, co-infection along with nicotine exposure in the development of premalignant/malignant lesions of the oral cavity in Indian population. Cancer Epidemiol. 2019;61:38–49.10.1016/j.canep.2019.05.00331129425
  19. 19. Barros MR, de Oliveira THA, de Melo CML, Venuti Ad de Freitas AC. Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers. J Immunol Res. 2018.10.1155/2018/2912671595492129854832
  20. 20. Smith M, García-Martínez E, Pitter M, Fucikova J, Spisek R, Zitvogel Ld et al. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology. 2018;7(12):1–15.10.1080/2162402X.2018.1526250627932530524908
DOI: https://doi.org/10.2478/cipms-2020-0038 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 225 - 227
Submitted on: Feb 21, 2020
|
Accepted on: Jul 16, 2020
|
Published on: Jan 29, 2021
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2021 Anna Dworzanska, Małgorzata Polz-Dacewicz, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.